Brazilian researchers have found out that drug erlotinib in combination with cisplatin-based chemoradiation therapy (CRT) can prove very effective in the treatment of cervical cancer.
In the experiment, the drug targets the epidermal growth factor receptor (EGFR) - a receptor that is usually produced in excess in cervical cancer patients.
AdvertisementAs part of the study, the research team, led by Dr Angélica Nogueira-Rodrigues of the Brazilian National Cancer Institute, carried out the test on 36 women in the age group of 18-70 years and who had cervical cancer stages IIB to IIIB. After an average of 77-day therapy, cancerous tumours vanished in 34 (94.4%) patients.
At 2 years after the treatment was stopped, 91.7% of the patients were alive and there was no progress in the disease for 80.6% patients. Even after one year, 80% of the women were alive and there was no progress in the disease for 73.8% women.
Researchers said, "To the best of our knowledge, the current study is the first to reveal that a target agent is safe and has promising activity against locally advanced cervical cancer when combined with CRT."
Until now, for patients suffering from locally advanced cervical cancer, cisplatin-based CRT is considered the standard treatment. But the researchers said that at times the therapy can be unpredictable and disappointing for patients.
The study was published in Cancer.
You May Also Like